The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters. ...

Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Dogs of the Dow to Invest in. BofA Turns More Positive on Merck (MRK) Pipeline Photo by Dan Dennis on Unsplash On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating. The analyst said the stock is starting to look more appealing as the pipeline has “rounded out,” and noted that the firm is now basing its valuation on a new FY27 EPS estimate. That optimism comes against a mixed backd ...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s ahead for MRK stock?The trial showed Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically significant and clinically meani ...

Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month after the company laid out a cautious 2026 outlook, acknowledging that the post-COVID reset isn't over yet. Track PFE stock here.Management flagged flat-to-low single-digit growth expectations, with COVID product declines continuing to fade out of the base. The market's response was telling: shares slipped, but ...

Key Points Pfizer has a substantial 6.6% dividend yield but a payout ratio exceeding 100%. Eli Lilly has a payout ratio of roughly 30%, but its dividend yield is a tiny 0.6%. Long-term income investors can find the middle ground with a 3.4% yield and a 45% payout ratio from Merck. 10 stocks we like better than Merck › Dividend investors need to be cautious about reaching too far for yield since this can open them up to added risks. At the same time, they must ensure that they are generating an a ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV- 304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signific. ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves Photo by Annie Spratt on Unsplash On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm said many of the policy concerns that weighed on the sector this year are likely to ...

Key Takeaways MRK gets positive CHMP opinion for expanded Winrevair use in adult PAH patients with WHO FC II, III and IV.The recommendation is based on phase III ZENITH data showing a 76% reduction in morbidity and mortality risk.The opinion will be reviewed by the European Commission, with a final decision expected in Q1 2026.Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending approval of an expanded ...

北京市贸促会党组书记、北京国际商会会长章建伟指出，举办"京品出海"系列活动的核心是为企业搭建 精准高效的对接平台，切实助力企业开拓海外市场。专委会将紧密围绕企业实际需求，成为连接政府与 市场、国内与国际的重要桥梁。 据介绍，目前副中心已被纳入全市医药健康产业"多点"优势布局，漷县镇集聚区已吸引包括4家上市企 业在内的众多创新主体落户，预计今年产值达60亿元，明年目标突破百亿元。 新京报讯(记者陈琳)近日，由北京市贸促会、北京国际商会主办的"京品出海"医药健康行业专场分享会 举办。会上，北京国际商会医药健康专业委员会正式揭牌成立，标志着北京在推动医药健康产业国际化 方面迈出关键一步。活动吸引了来自全球多地的专业机构代表及150余家国内外企业参会。 在当前全球科技革命与产业变革加速的背景下，医药健康产业已成为创新最活跃的赛道之一。推动"京 品"医药健康产品与服务开拓国际市场，是企业提升竞争力的必然选择。新成立的医药健康专业委员会 由北京医药行业协会倡议发起，联合默沙东、赛诺菲、阿斯利康、强生等25家国内外知名企业共同组 成，旨在聚焦行业国际化发展的共性需求，提供政策解读、市场对接、合规指导等全链条服务。 ...

Core Viewpoint - Merck is strategically focusing on long-term growth through new product launches and a robust pipeline as its leading drug, Keytruda, is set to lose patent protection in 2028 [1][2]. Pipeline and Product Development - Keytruda, which accounts for over 50% of Merck's pharmaceutical sales, generated $23.3 billion in sales during the first nine months of 2025, reflecting an 8% year-over-year increase [2]. - The company's phase III pipeline has nearly tripled since 2021, with plans to launch around 20 new vaccines and drugs in the coming years, many of which have blockbuster potential [3][11]. - Notable new products include the 21-valent pneumococcal conjugate vaccine, Capvaxive, and the pulmonary arterial hypertension drug, Winrevair, both of which are expected to significantly contribute to revenue post-Keytruda exclusivity [4][11]. Strategic Mergers and Acquisitions - Merck has engaged in substantial M&A activities, including a recent agreement to acquire Cidara Therapeutics for $9.2 billion, which will enhance its portfolio with CD388 for seasonal influenza prevention [7][8]. - Earlier this year, Merck acquired Verona Pharma for $10 billion, adding Ohtuvayre, a novel treatment for chronic obstructive pulmonary disease [8]. Competitive Landscape - Keytruda faces competition from other PD-L1 inhibitors such as Bristol Myers' Opdivo, Roche's Tecentriq, and AstraZeneca's Imfinzi, which are also approved for multiple cancer types [10][12][13]. Financial Performance and Valuation - Year-to-date, Merck's shares have decreased by 0.4%, underperforming the industry average of 13.6% [14]. - The company's price/earnings ratio stands at 11.22, which is lower than the industry average of 16.59 and its 5-year mean of 12.51, indicating a potentially attractive valuation [15]. - The Zacks Consensus Estimate for 2025 earnings per share has slightly increased from $8.94 to $8.98, while the estimate for 2026 has decreased from $9.46 to $8.81 [18].